Related Experiment Video
Updated: Aug 28, 2025
09:31
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.7K
Amyloid-β: Structure, Function, and Pathophysiological Significance in Neurodegenerative Diseases
Satoshi Saito1, Kenjiro Ono2, Masashi Tanaka3
1Department of Neurology, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Osaka 564-8565, Japan.
International Journal of Molecular Sciences
|September 23, 2022
Summary
Dementia rates are rising globally, yet effective treatments remain elusive. This research explores novel therapeutic avenues to combat this growing neurodegenerative disease crisis.
Area of Science:
- Neuroscience
- Gerontology
- Pathology
Background:
- The global prevalence of dementia is escalating, posing a significant public health challenge.
- Current therapeutic options for dementia are limited, highlighting an urgent need for innovative treatments.
Discussion:
- This study investigates emerging therapeutic strategies for dementia.
- Focus is placed on understanding the underlying mechanisms of neurodegeneration.
- Potential interventions are evaluated for their efficacy and safety.
Key Insights:
- Novel therapeutic targets for dementia have been identified.
- Early-stage research suggests promising results for specific interventions.
- Further investigation is required to translate these findings into clinical practice.
Outlook:
- Future research will focus on clinical trials to validate these findings.
- Development of effective dementia therapies could significantly improve patient outcomes.
- Advancements in this field may offer hope for millions affected by dementia worldwide.
More Related Videos
Related Concept Videos
03:03Amyloid Fibrils
9.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.7K
01:26Alzheimer's Disease: Overview
635
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
635
01:15Parkinson's Disease: Overview
672
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
672
01:13The Proteasome
1.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.1K
01:22Alzheimer's Disease: Treatment
248
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
248
01:22Protein Folding
119.5K
Overview
119.5K